[
  {
    "year": "1998 – 2001*",
    "tx": "Arsenic trioxide",
    "biomarker": "PML-RARɑ Fusion",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "Follow-on"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Denileukin diftitox",
    "biomarker": "CD25+",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Exemestane",
    "biomarker": "ER+",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Gemtuzumab ozogamicin",
    "biomarker": "CD33+",
    "biomarkerDetection": "Flow cytometry",
    "drugClassification": "NA"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Imatinib",
    "biomarker": "BCR-ABL1 Fusion (Ph+)",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "First-in-class"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Imatinib",
    "biomarker": "KIT+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Imatinib",
    "biomarker": "PDGFRA/B Fusions",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "First-in-class"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Imatinib",
    "biomarker": "PDGFB Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Imatinib",
    "biomarker": "FIP1L1-PDGFRA Fusion",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "1998 – 2001*",
    "tx": "Trastuzumab",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC or FISH or CISH",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2002",
    "tx": "Fulvestrant",
    "biomarker": "HR+/ HER2-",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2003",
    "tx": "Gefitinib",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2003",
    "tx": "Tositumomab and Iodine I 131 Tositumomab",
    "biomarker": "CD20+",
    "biomarkerDetection": "Flow cytometry",
    "drugClassification": "NA"
  },
  {
    "year": "2004",
    "tx": "Cetuximab",
    "biomarker": "KRAS Wildtype and EGFR-expressing",
    "biomarkerDetection": "DNA/NGS-based detection, IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2004",
    "tx": "Erlotinib",
    "biomarker": "EGFR L858R, Exon 19 Deletions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2006",
    "tx": "Dasatinib",
    "biomarker": "BCR-ABL1 Fusion",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Resistance"
  },
  {
    "year": "2006",
    "tx": "Panitumumab",
    "biomarker": "KRAS and NRAS Wildtype, EGFR-expressing",
    "biomarkerDetection": "DNA/NGS-based detection, IHC",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2006",
    "tx": "Sunitinib",
    "biomarker": "KIT+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Resistance"
  },
  {
    "year": "2007",
    "tx": "Lapatinib",
    "biomarker": "HER2 Overexpression",
    "biomarkerDetection": "DNA/NGS-based detection or IHC or FISH",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2007",
    "tx": "Nilotinib",
    "biomarker": "BCR-ABL1 Fusion (Ph+)",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "Resistance"
  },
  {
    "year": "2009",
    "tx": "Everolimus",
    "biomarker": "TSC1/2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2011",
    "tx": "Brentuximab",
    "biomarker": "CD30+",
    "biomarkerDetection": "Flow cytometry",
    "drugClassification": "NA"
  },
  {
    "year": "2011",
    "tx": "Crizotinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection or IHC or FISH",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2011",
    "tx": "Crizotinib",
    "biomarker": "ROS1+ (ROS1 Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2011",
    "tx": "Vemurafenib",
    "biomarker": "BRAF V600",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2012",
    "tx": "Bosutinib",
    "biomarker": "BCR-ABL1 Fusion (Ph+)",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "Resistance"
  },
  {
    "year": "2012",
    "tx": "Pertuzumab + Trastuzumab",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC or FISH or CISH",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2012",
    "tx": "Ponatinib",
    "biomarker": "BCR-ABL1 Fusion (Ph+)",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2012",
    "tx": "Ponatinib",
    "biomarker": "ABL1 T315I",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2012",
    "tx": "Regorafenib",
    "biomarker": "KIT+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Resistance"
  },
  {
    "year": "2013",
    "tx": "Ado-trastuzumab emtansine",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC or FISH or CISH",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2013",
    "tx": "Afatinib",
    "biomarker": "EGFR L858R, G719X, L861Q, S768I, Exon 19 Deletions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2013",
    "tx": "Dabrafenib",
    "biomarker": "BRAF V600E/K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2013",
    "tx": "Ibrutinib",
    "biomarker": "17p del",
    "biomarkerDetection": "FISH",
    "drugClassification": "NA"
  },
  {
    "year": "2013",
    "tx": "Trametinib",
    "biomarker": "BRAF V600E/K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Blinatumomab",
    "biomarker": "CD19+",
    "biomarkerDetection": "Flow cytometry",
    "drugClassification": "NA"
  },
  {
    "year": "2014",
    "tx": "Ceritinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Resistance"
  },
  {
    "year": "2014",
    "tx": "Dabrafenib + Trametinib",
    "biomarker": "BRAF V600E/K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Nivolumab",
    "biomarker": "MSI-H",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2014",
    "tx": "Olaparib",
    "biomarker": "BRCA1/2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Olaparib",
    "biomarker": "ATM, BARD1, BRCA1/2, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "MSI-H",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "TMB-H",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "PD-L1 Expression",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "dMMR",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2014",
    "tx": "Pembrolizumab",
    "biomarker": "pMMRe",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2015",
    "tx": "Alectinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Resistance"
  },
  {
    "year": "2015",
    "tx": "Cobimetinib + Vemurafenib",
    "biomarker": "BRAF V600E/K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2015",
    "tx": "Ipilimumab + Nivolumab",
    "biomarker": "MSI-H",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2015",
    "tx": "Ipilimumab + Nivolumab",
    "biomarker": "dMMR",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2015",
    "tx": "Ipilimumab + Nivolumab",
    "biomarker": "PD-L1 Expressing",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2015",
    "tx": "Osimertinib",
    "biomarker": "EGFR T790M, L858R and Exon 19 Deletions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2015",
    "tx": "Palbociclib",
    "biomarker": "HR+/ HER2-",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2016",
    "tx": "Atezolizumab",
    "biomarker": "PD-L1 Expressing",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2016",
    "tx": "Rucaparib",
    "biomarker": "BRCA1/2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2017",
    "tx": "Abemaciclib",
    "biomarker": "HR+/ HER2-",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2017",
    "tx": "Brigatinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection or FISH",
    "drugClassification": "Resistance"
  },
  {
    "year": "2017",
    "tx": "Enasidenib",
    "biomarker": "IDH2 R140, R172",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2017",
    "tx": "Midostaurin",
    "biomarker": "FLT3 I836, 572_630ins, D835",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2017",
    "tx": "Neratinib",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2017",
    "tx": "Niraparib",
    "biomarker": "BRCA1/2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2017",
    "tx": "Ribociclib",
    "biomarker": "HR+/ HER2-",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2018",
    "tx": "Binimetinib + Encorafenib",
    "biomarker": "BRAF V600E/K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2018",
    "tx": "Cemiplimab",
    "biomarker": "PD-L1 Expression",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2018",
    "tx": "Dacomitinib",
    "biomarker": "EGFR L858R and Exon 19 Deletions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2018",
    "tx": "Gilteritinib",
    "biomarker": "FLT3 I836, 572_630ins, D835",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2018",
    "tx": "Ivosidenib",
    "biomarker": "IDH1 R132",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2018",
    "tx": "Larotrectinib",
    "biomarker": "NTRK1/2/3 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2018",
    "tx": "Lorlatinib",
    "biomarker": "ALK+ (ALK Fusions)",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Resistance"
  },
  {
    "year": "2018",
    "tx": "Lutetium Lu 177 dotatate",
    "biomarker": "Somatostatin Receptor",
    "biomarkerDetection": "Radionucleotide scan",
    "drugClassification": "NA"
  },
  {
    "year": "2018",
    "tx": "Talazoparib",
    "biomarker": "BRCA1/2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2018",
    "tx": "Talazoparib",
    "biomarker": "ATM, ATR, BRCA1/2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2019",
    "tx": "Alpelisib + Fulvestrant",
    "biomarker": "PIK3CA E545G, Q546E, E545A, H1047R, C420R, H1047Y, Q546R, H1047L, E542K, E545D, E545K",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2019",
    "tx": "Entrectinib",
    "biomarker": "NTRK1/2/3 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2019",
    "tx": "Entrectinib",
    "biomarker": "ROS1 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2019",
    "tx": "Erdafitinib",
    "biomarker": "FGFR2 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2019",
    "tx": "Erdafitinib",
    "biomarker": "FGFR3 Fusions, S249C, R248C, G370C, Y373C",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2019",
    "tx": "Trastuzumab Deruxtecan",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2019",
    "tx": "Trastuzumab Deruxtecan",
    "biomarker": "HER2-low",
    "biomarkerDetection": "IHC",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2019",
    "tx": "Trastuzumab Deruxtecan",
    "biomarker": "ERBB2 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Atezolizumab + Vemurafenib + Cobimetinib",
    "biomarker": "BRAF V600",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Avapritinib",
    "biomarker": "PDGFRA Exon 18 Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Avapritinib",
    "biomarker": "KIT D816",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Capmatinib",
    "biomarker": "MET Exon 14 Skipping Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Encorafenib + Cetuximab",
    "biomarker": "BRAF V600E",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Margetuximab",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2020",
    "tx": "Pemigatinib",
    "biomarker": "FGFR2 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2020",
    "tx": "Pemigatinib",
    "biomarker": "FGFR1 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2020",
    "tx": "Pralsetinib",
    "biomarker": "RET Fusions and Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Ripretinib",
    "biomarker": "KIT+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2020",
    "tx": "Selpercatinib",
    "biomarker": "RET Fusions and Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Selumetinib",
    "biomarker": "NF1 Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Tazemetostat",
    "biomarker": "EZH2 Y646F, A692V, Y646C, Y646S, Y646N, Y646H, A682G",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Tazemetostat",
    "biomarker": "SMARCB1 Deletion",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2020",
    "tx": "Tucatinib + Trastuzumab",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection or IHC",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2020",
    "tx": "Tucatinib + Trastuzumab",
    "biomarker": "KRAS and NRAS Wildtype and HER2+",
    "biomarkerDetection": "DNA/NGS-based detection, DNA/NGS-based detection or IHC or ISH",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2020",
    "tx": "Sacituzumab govitecan",
    "biomarker": "HR+/HER2-",
    "biomarkerDetection": "IHC or IHC + ISH",
    "drugClassification": "NA"
  },
  {
    "year": "2021",
    "tx": "Amivantamab",
    "biomarker": "EGFR Exon 20 Insertions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2021",
    "tx": "Asciminib",
    "biomarker": "BCR-ABL1 Fusion and ABL1 T315I",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Resistance"
  },
  {
    "year": "2021",
    "tx": "Belzutifan",
    "biomarker": "VHL Oncogenic Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2021",
    "tx": "Dostarlimab",
    "biomarker": "dMMR",
    "biomarkerDetection": "IHC",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2021",
    "tx": "Dostarlimab",
    "biomarker": "MSI-H",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2021",
    "tx": "Infigratinib",
    "biomarker": "FGFR2 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2021",
    "tx": "Mobocertinib",
    "biomarker": "EGFR Exon 20 Insertions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2021",
    "tx": "Sotorasib",
    "biomarker": "KRAS G12C",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2021",
    "tx": "Tepotinib",
    "biomarker": "MET Exon 14 Skipping Mutations",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2021",
    "tx": "Trastuzumab + Pembrolizumab",
    "biomarker": "HER2+",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "First-in-class"
  },
  {
    "year": "2022",
    "tx": "Futibatinib",
    "biomarker": "FGFR2 Fusions",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Follow-on"
  },
  {
    "year": "2022",
    "tx": "Pluvicto",
    "biomarker": "PSMA+",
    "biomarkerDetection": "PET imaging",
    "drugClassification": "NA"
  },
  {
    "year": "2022",
    "tx": "Tebentafusp",
    "biomarker": "HLA-A*02:01-positivity",
    "biomarkerDetection": "DNA/HLA-typing",
    "drugClassification": "NA"
  },
  {
    "year": "2022",
    "tx": "Olutasidenib",
    "biomarker": "IDH1 R132C/G/H/L/S",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2022",
    "tx": "Mirvetuximab soravtansine",
    "biomarker": "FRɑ",
    "biomarkerDetection": "IHC",
    "drugClassification": "NA"
  },
  {
    "year": "2023",
    "tx": "Quizartinib",
    "biomarker": "FLT3 ITD",
    "biomarkerDetection": "DNA/NGS-based detection",
    "drugClassification": "Mechanistically-distinct"
  },
  {
    "year": "2023",
    "tx": "Elacestrant",
    "biomarker": "ESR1 Ligand-binding domain missense mutations and ER+/HER2-",
    "biomarkerDetection": "DNA/NGS-based detection, IHC",
    "drugClassification": "First-in-class"
  }
]
